Business Context and Reporting Period
This Form 8-K Current Report was filed by Amneal Pharmaceuticals, Inc. on January 7, 2019, covering events that occurred on January 2, 2019, and January 4, 2019. The filing primarily addresses executive officer changes within the company's legal and corporate governance structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the restructuring of the company's senior legal leadership:
- Appointment: David A. Buchen was appointed as Senior Vice President, Chief Legal Officer, and Corporate Secretary.
- Departure: Sheldon V. Hirt, the former Senior Vice President, General Counsel, and Corporate Secretary, will depart the company following a transition period concluding in January 2019.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, future outlook, or specific risk factors. The document notes that the press release regarding these changes (Exhibit 99.1) is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its liability status.
Investor Verification Checklist
- Verify the effective date of David A. Buchen's appointment and the completion of the transition period for Sheldon V. Hirt.
- Review the attached press release (Exhibit 99.1) for additional context on the reasons for the leadership change.
- Confirm that no other undisclosed executive changes occurred during the transition period.